Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Onfi (clobazam) is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.
• This summary is based on the review of eight systematic review(s)/meta-analysis(es). ^[1-8]
• Cannabidiol (CBD) showed significant effectiveness in reducing seizure frequency in patients with Dravet syndrome (DS), Lennox-Gastaut syndrome (LGS), and tuberous sclerosis complex (TSC), with enhanced efficacy when used in combination with clobazam.
• High-dose clobazam (CLB_H) was significantly associated with a ≥50% reduction in drop seizure frequency and had the highest efficacy ranking among antiepileptic drugs (AEDs) in both short-term and long-term outcomes.
• Clobazam did not demonstrate significant differences compared to other AEDs in overall seizure cessation or reduction according to high-certainty evidence.
• Common adverse drug reactions (ADRs) included nervous system disorders, severe skin reactions, respiratory infections, and one death due to aspiration pneumonia. Significant concerns included severe skin reactions, respiratory infections/inflammations, central sedation, and interactions with CYP3A4 or CYP2C19 inhibitors.
• High-certainty evidence indicated a high rate of adverse events leading to study discontinuation with add-on clobazam and other ASMs.
• Patients on clobazam in combination with CBD experienced increased incidences of somnolence, sedation, and elevated transaminases.
• Clobazam was associated with adverse events such as drowsiness, and there was a slightly higher incidence of treatment discontinuation due to adverse events.